Replimune Group Inc (REPL)
Replimune Group Inc is a clinical-stage biotechnology company focused on developing and commercializing oncolytic immunotherapies for cancer. Its programs are designed to stimulate the immune system against tumors through proprietary product candidates. The company’s lead candidate, RP1, is a selectively replicating HSV-1-based therapy that includes GALV-GP R(-) and human GM-CSF and is being studied across a range of solid tumors. Replimune is also advancing RP2, which is designed to express an anti-CTLA-4 antibody-like protein to help counter CTLA-4-mediated immune suppression, and RP3, which is intended to express immune-activating proteins that stimulate T cells. Founded in 2015, Replimune is headquartered in Woburn, Massachusetts, and its common stock trades on NASDAQ under the ticker REPL.
Jump between the core stock analysis sections, valuation data, fair value models, technical outlook, and FAQ.
| Ticker | Fair Value | Fair Value Upside/Downside | Fair Value Rating | Analyst Price Target | Analyst Target Upside/Downside | Analyst Target Rating | Overall Financial Health | Upcoming Dividend Ex-Date | Dividend Payment Date | Upcoming Dividend | Dividend Yield | Next Earnings Date | P/E Ratio | Price-to-Book Ratio | Price-to-Sales Ratio | Market Cap | Enterprise Value | Total Debt / Total Capital | Free Float / Shares Outstanding | Altman Z-Score | Payout Ratio | Free Cash Flow / Net Income |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
NASDAQ-REPL
|
$10.89
|
-0.4% Downside
|
Fair
|
$10.67
|
-2.5% Downside
|
Fair
|
Weak
|
—
|
—
|
—
|
0.0%
|
July 30, 2026
|
-2.9x
|
5.6x
|
—
|
882.3 M
|
766.1 M
|
11.2%
|
71.1%
|
-4.5
|
—
|
90.6%
|
